Why Rivaroxaban (Xarelto) Is Approved for PAD but Apixaban (Eliquis) Is Not
Rivaroxaban at the specific dose of 2.5 mg twice daily combined with aspirin is the only anticoagulant regimen proven in large randomized trials to reduce both major adverse cardiovascular events and major adverse limb events in peripheral artery disease, while apixaban has never been studied in PAD and has no FDA indication for this condition. 1, 2, 3
The Evidence Base for Rivaroxaban in PAD
The approval of rivaroxaban for PAD rests on two landmark trials that specifically enrolled PAD patients and used a unique low-dose regimen (2.5 mg twice daily) combined with aspirin:
The COMPASS trial (27,395 patients with stable atherosclerotic disease, including 7,470 with PAD) demonstrated that rivaroxaban 2.5 mg twice daily plus aspirin reduced major adverse cardiovascular events by 24% (HR 0.76,95% CI 0.66–0.86, p<0.001) and major adverse limb events by 46% (HR 0.54,95% CI 0.35–0.82) compared with aspirin alone. 1, 2
The VOYAGER PAD trial (6,564 patients after lower-extremity revascularization) showed a 15% relative risk reduction in the composite of acute limb ischemia, major amputation, myocardial infarction, ischemic stroke, or cardiovascular death (HR 0.85,95% CI 0.76–0.96) with the same low-dose rivaroxaban-plus-aspirin regimen. 1, 3
These trials established that the specific low-dose formulation of rivaroxaban (2.5 mg twice daily, not the full anticoagulation dose of 20 mg daily) provides dual pathway inhibition—blocking both platelet activation through aspirin and Factor Xa through rivaroxaban—which addresses the thrombotic mechanisms in PAD. 1, 4
Why Apixaban Has No Role in PAD
Apixaban has never been studied in clinical trials for peripheral artery disease and therefore has no evidence base or FDA approval for this indication. 1, 5, 6
The FDA label for apixaban (Eliquis) lists only three approved indications: (1) reducing stroke risk in nonvalvular atrial fibrillation, (2) treatment and prevention of venous thromboembolism, and (3) prophylaxis after hip or knee replacement surgery. PAD is not mentioned anywhere in the apixaban prescribing information. 6
The pivotal apixaban trials (ARISTOTLE for atrial fibrillation, AMPLIFY for VTE) did not enroll patients based on PAD status and did not evaluate limb outcomes. 6
Current guidelines explicitly state that apixaban should not be used for PAD unless the patient has a separate indication requiring full anticoagulation (such as atrial fibrillation), in which case apixaban monotherapy—not combined with antiplatelet therapy—is recommended. 1, 5
Current Guideline Recommendations
The 2024 ACC/AHA PAD Guidelines provide a Class I (strongest) recommendation for rivaroxaban 2.5 mg twice daily plus aspirin 75–100 mg daily in patients with symptomatic PAD to reduce major adverse cardiovascular and limb events. 1, 4
The same Class I recommendation applies after lower-extremity revascularization, with therapy initiated within 10 days of the procedure. 1, 4
The 2024 ESC Guidelines recommend aspirin plus rivaroxaban 2.5 mg twice daily (Class IIa) for patients with PAD and high-risk features (previous amputation, chronic limb-threatening ischemia, previous revascularization, heart failure, diabetes, vascular disease in ≥2 beds, or eGFR <60 mL/min/1.73 m²) without high bleeding risk. 7, 4
Critical Distinctions and Pitfalls to Avoid
Do not confuse full-dose anticoagulation with the low-dose rivaroxaban regimen used in PAD:
Full-dose apixaban (5 mg twice daily) or full-dose rivaroxaban (20 mg daily) for anticoagulation should never be prescribed for PAD alone, as these doses increase bleeding risk without reducing cardiovascular or limb events. 1, 5
The therapeutic benefit in PAD comes specifically from rivaroxaban 2.5 mg twice daily combined with aspirin—this is a unique dual pathway inhibition strategy, not standard anticoagulation. 1, 2
If a PAD patient requires full anticoagulation for another indication (e.g., atrial fibrillation), use apixaban monotherapy at standard AF dosing without adding antiplatelet agents, as triple therapy dramatically increases bleeding risk. 1, 5
When rivaroxaban is contraindicated (history of intracranial hemorrhage, GI bleeding within 6 months, eGFR <15 mL/min, or dialysis), the alternative is aspirin plus clopidogrel for 1–6 months after revascularization, then transition to single antiplatelet therapy. 1, 4
Safety Profile
Adding low-dose rivaroxaban to aspirin increased major bleeding (HR 1.70,95% CI 1.40–2.05), primarily gastrointestinal, but did not increase intracranial or fatal bleeding rates. 1, 2
The net clinical benefit (ischemic events prevented minus fatal/critical-organ bleeding) favored the rivaroxaban-aspirin combination (HR 0.80,95% CI 0.70–0.91). 1
In the VOYAGER PAD trial, TIMI major bleeding did not differ significantly between rivaroxaban-aspirin and aspirin alone (HR 1.43,95% CI 0.97–2.10, p=0.07), though ISTH major bleeding was higher (HR 1.42,95% CI 1.10–1.84, p=0.007). 3
The Bottom Line
Rivaroxaban's approval for PAD stems from dedicated, large-scale randomized trials that tested a specific low-dose formulation in combination with aspirin and demonstrated reductions in both cardiovascular and limb events. Apixaban has never undergone similar testing in PAD patients, has no supporting evidence, and therefore has no FDA indication or guideline recommendation for this condition. 1, 2, 3